SEARCH

SEARCH BY CITATION

References

  • 1
    Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003; 23: 89.
  • 2
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
  • 3
    Perrillo RP, Wright T, Rakela J, et al. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433.
  • 4
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741.
  • 5
    Tillmann HL, Klempnauer J, Manns MP. Risks and benefits of nucleosides before and after liver transplantation. Transplant Proc 2003; 35: 2086.
  • 6
    Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527.
  • 7
    Roseneau J, Bahr MJ, Tillman HL, et al. Lamivudine and low dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895.
  • 8
    Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DADP, penciclovir and lobucavir. J Viral Hepat 2000; 7: 161.
  • 9
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808.
  • 10
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800.
  • 11
    Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre and post-liver transplantation patients. Hepatology 2003; 38: 1419.
  • 12
    James JS. Tenofovir approved: broad indication. AIDS Treat News 2001; 26: 2.
  • 13
    Van Bömmel F, Schernick A, Hopf U, et al. Tenofovir dipivoxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124: 586.
  • 14
    Van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421.
  • 15
    Schildgen O, Schewe CK, Voget M, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004; 18: 2325.
  • 16
    Zoulim F. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy? Hepatology 2003; 38: 1353.
  • 17
    Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterol Hepatol 2004; 2: 87.
  • 18
    Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002; 123: 2135.
  • 19
    Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54: 37.
  • 20
    Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17: F7.
  • 21
    Nuñez M, Perez-Olmeda M, Diaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352.
  • 22
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 177.
  • 23
    Van Bómmel F, Wünsche T, Schümann D, et al. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36: 507.
  • 24
    Ristig M, Drechsler H, Crippin J, et al. Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus. AIDS Patient Care STDS 2003; 17: 439.
  • 25
    Nery JR, Lau D, Nery C, et al. Tenofovir and HBV Mutants after Liver Transplantation. Washington DC: American Transplant Congress (ATC), 2003 [Abstract 1095].
  • 26
    Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49: 860.
  • 27
    Tillmann HL, Bock CT, Bleck JS, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003; 9: 191.
  • 28
    Westland CE, Yang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96.
  • 29
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292.
  • 30
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudina-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266.
  • 31
    de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on hepatitis B. Consensus Statement (long version). J Hepatol 2003; 39 (Suppl. 1): S3S25.
  • 32
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant Hepatitis B virus. Gastroenterology 2004; 126: 81.
  • 33
    Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic Hepatitis B. Hepatology 2003; 38: 545.